Vincent Duval
About
Vincent Duval is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Vincent Duval has authored 24 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Vincent Duval's work include Cancer Treatment and Pharmacology (7 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Advanced Breast Cancer Therapies (5 papers). Vincent Duval is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Advanced Breast Cancer Therapies (5 papers). Vincent Duval collaborates with scholars based in Switzerland, France and Spain. Vincent Duval's co-authors include Mats O. Karlsson, Ulrike Graefe‐Mody, Silke Retlich, Ulrich Jaehde, Alexander Staab, Jordi Rodón, Carolyn D. Britten, Cornelia Quadt, José Baselga and Arvid Jungnik and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Vincent Duval
23 papers receiving 362 citations
Peers
Vincent Duval
Matthew M. Riggs United States
Kehua Wu United States
Mandana Hasanzad Iran
Michael Palmer United States
Linda P. Briley United States
Kevin Rockich United States
Ruth Roberts United Kingdom
Anne Rosselet Switzerland
Kanji Komatsu Japan
Citations per year, relative to Vincent Duval Vincent Duval (= 1×)
peers
Matthew M. Riggs
Countries citing papers authored by Vincent Duval
Since
Specialization
Citations
This map shows the geographic impact of Vincent Duval's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Duval with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Duval more than expected).
Fields of papers citing papers by Vincent Duval
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Vincent Duval. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Duval. The network helps show where Vincent Duval may publish in the future.
Co-authorship network of co-authors of Vincent Duval
This figure shows the co-authorship network connecting the top 25 collaborators of Vincent Duval. A scholar is included among the top collaborators of Vincent Duval based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent Duval. Vincent Duval is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Duval, Vincent, Icía Santos‐Zas, Corinne Tanchot, et al.. (2025). Targeting CD8+ T cells in cardiovascular diseases: current options and therapeutic perspectives. Cardiovascular Research. 121(12). 1830–1842.
2.
He, Zhijian, Vincent Duval, António Gonçalves, et al.. (2023). Population Pharmacokinetics and Exposure–Response Analysis for the CTLA‐4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study. Clinical Pharmacology & Therapeutics. 114(6). 1375–1386.
3.
Wagner, Nathalie, Vincent Duval, Jonathan I. Silverberg, et al.. (2023). Selection of Nemolizumab Clinical Dosage for Atopic Dermatitis. Journal of Drugs in Dermatology. 22(10). 1017–1020.
4.
Alayrac, Paul, Vincent Duval, Mathilde Lemitre, et al.. (2022). Role of tissue resident VSIG4+ macrophages in cardiac remodeling after acute myocardial infarction in mice. Archives of Cardiovascular Diseases Supplements. 14(2). 168–168.
5.
Retout, Sylvie, et al.. (2022). A Pharmacokinetics–Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B. Clinical Pharmacology & Therapeutics. 112(2). 372–381.
6.
Rodón, Jordi, José Alejandro Pérez Fidalgo, Ian E. Krop, et al.. (2018). Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. 82(2). 285–298.
7.
Ouatas, Taoufik, et al.. (2017). Concomitant Use of Midostaurin with Strong CYP3A4 Inhibitors: An Analysis from the Ratify Trial. Blood. 130. 3814–3814.
8.
Wu, Yi‐Long, Lucia Trandafir, Tuochuan Dong, et al.. (2016). Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors. Anticancer Research. 36(11). 6185–6194.
9.
Csonka, Dénes, et al.. (2015). A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment. The Journal of Clinical Pharmacology. 56(3). 316–323.
10.
Retlich, Silke, Vincent Duval, Ulrike Graefe‐Mody, et al.. (2015). Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus. Clinical Pharmacokinetics. 54(7). 737–750.
11.
Schüler, Martin, Jean‐Pascal Machiels, Dagmar Hess, et al.. (2014). Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).. Journal of Clinical Oncology. 32(15_suppl). 627–627.
12.
Rodón, Jordi, Martin Schüler, Jean‐Pascal Machiels, et al.. (2014). Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).. Journal of Clinical Oncology. 32(15_suppl). 621–621.
13.
Iwata, Hiroji, José Baselga, Mario Campone, et al.. (2013). Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.. Journal of Clinical Oncology. 31(15_suppl). TPS650–TPS650.
14.
Campone, Mario, P. Fumoleau, Marta Gil-Martín, et al.. (2012). Abstract P6-11-08: A multicenter, open-label Ph IB/II study of BEZ235, an oral dual PI3K/mTOR inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer. Cancer Research. 72(24_Supplement). P6–11.
15.
Peyton, James D., Jordi Rodón, Carolyn D. Britten, et al.. (2011). A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3066–3066.
16.
Bottino, Dean, Josep Tabernero, Howard A. Burris, et al.. (2011). Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235.. Journal of Clinical Oncology. 29(15_suppl). 3056–3056.
17.
Retlich, Silke, Vincent Duval, Ulrike Graefe‐Mody, Ulrich Jaehde, & Alexander Staab. (2010). Impact of Target‐Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP‐4 Inhibition in Type 2 Diabetic Patients. The Journal of Clinical Pharmacology. 50(8). 873–885.
18.
Retlich, Silke, Vincent Duval, Arne Ring, et al.. (2010). Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects. Clinical Pharmacokinetics. 49(12). 829–840.
19.
Chenel, Marylore, Kayode Ogungbenro, Vincent Duval, et al.. (2005). Optimal Blood Sampling Time Windows for Parameter Estimation Using a Population Approach: Design of a Phase II Clinical Trial. Journal of Pharmacokinetics and Pharmacodynamics. 32(5-6). 737–756.
20.
Duval, Vincent & Mats O. Karlsson. (2002). Impact of Omission or Replacement of Data Below the Limit of Quantification on Parameter Estimates in a Two-Compartment Model. Pharmaceutical Research. 19(12). 1835–1840.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Matthew M. Riggs Breakdown of academic impact, for papers by Kehua Wu Breakdown of academic impact, for papers by Mandana Hasanzad Breakdown of academic impact, for papers by Michael Palmer Breakdown of academic impact, for papers by Linda P. Briley Breakdown of academic impact, for papers by Kevin Rockich Breakdown of academic impact, for papers by Ruth Roberts Breakdown of academic impact, for papers by Anne Rosselet Breakdown of academic impact, for papers by Kanji Komatsu